Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry.

CCR7 T-cell/histiocyte-rich large B-cell lymphoma antigen expression classic Hodgkin lymphoma diffuse large B-cell lymphoma flow cytometry immunohistochemistry nodular lymphocyte predominant Hodgkin lymphoma primary mediastinal large B-cell lymphoma “grey zone” lymphoma

Journal

American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470

Informations de publication

Date de publication:
16 Sep 2024
Historique:
received: 06 05 2024
accepted: 16 08 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 17 9 2024
Statut: aheadofprint

Résumé

Classic Hodgkin lymphoma (CHL) is characterized by infrequent neoplastic Hodgkin and Reed-Sternberg (HRS) cells in an inflammatory background. The diagnostic utility of CC-chemokine receptor 7 (CCR7) in CHL was explored using flow cytometry and immunohistochemistry (IHC). Neoplastic specimens and non-neoplastic lymph nodes were immunophenotyped and CCR7 expression was measured semiquantitatively by flow cytometry (clone 3D12) and IHC (clone 150503). Our results showed that CCR7 was expressed on HRS cells in the vast majority of CHL cases (45/48 by flow cytometry, 57/59 by IHC) but rarely expressed in neoplastic cells in diffuse large B-cell lymphoma, not otherwise specified (1/25 by flow cytometry, 2/40 by IHC) and nodular lymphocyte predominant Hodgkin lymphoma (0/4 by flow cytometry, 1/13 by IHC). Primary mediastinal large B-cell lymphoma (PMLBCL) revealed weak CCR7 expression by flow cytometry in most cases (8/10) but only occasionally by IHC (2/12). Both cases (2/2) of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) also showed CCR7 expression detected by flow cytometry compared with IHC (0/7). The HRS cells demonstrated a greater percentage of positive cells and greater antigen intensity than the other B-cell lymphomas by IHC. The expression identified by flow cytometry in PMLBCL and THRLBCL but not by IHC suggests that there may be differences in the detection capabilities of the 2 techniques or the 2 CCR7 clones used. The expression of CCR7 in HRS cells suggests its potential utility in differentiating CHL from other B-cell lymphomas. Incorporating CCR7 into flow cytometry and IHC panels may further enhance the diagnostic sensitivity of CHL.

Identifiants

pubmed: 39288406
pii: 7759700
doi: 10.1093/ajcp/aqae119
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Xueyan Chen (X)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, US.
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, US.

Lori Soma (L)

Department of Pathology, City of Hope, Duarte, CA, US.

Claire Murphy (C)

Pathology Consultants, PC, Eugene/Springfield Lab, Springfield, OR, US.

Maria Tretiakova (M)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, US.

Kikkeri N Naresh (KN)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, US.
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, US.

Jonathan R Fromm (JR)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, US.

Classifications MeSH